Excedrin Migraine Has Untapped Growth Potential, Novartis Says
This article was originally published in The Tan Sheet
Novartis sees further promotion of Excedrin Migraine as an "unexploited opportunity" to expand the brand's presence and grow the firm's OTC category
You may also be interested in...
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20
Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation